Physician profile
David B Maxwell
NPI 1245290907
$2,647.42
in general payments reported to CMS, 2019-2025
17 companies · $94.99 in 2025
The $94.99 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $782 · 2021: $724 · 2022: $15.91 · 2025: $94.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $561.00 | 2019-2021 | |
| Abbvie INC. | $507.55 | 2019-2021 | |
| Amgen INC. | $405.22 | 2019-2022 | |
| Janssen Biotech, INC. | $240.29 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $220.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $130.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $94.36 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $90.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.90 | 2019-2020 | |
| Celgene Corporation | $78.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $75.35 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $42.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.58 | 2021 | |
| Aurinia Pharma U.S., INC. | $20.38 | 2021 | |
| Genentech USA, INC. | $19.82 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $18.20 | 2019 | |
| Genzyme Corporation | $16.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.